Join
Live feed
·
PRReleasevia Quantisnow
Protalix BioTherapeutics Inc. (DE) logo

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

ByQuantisnow·Wall Street's wire, on your screen.
PLX· Protalix BioTherapeutics Inc. (DE)
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLX (Protalix BioTherapeutics Inc. (DE)) and more on Quantisnow.

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU | Quantisnow